M2 Presswire - Research and Markets: Analyze How Wyeth Will Perform In Light Of Patent Expiry for the Key Effexor and Protonix Franchises Prior To 2012.
M2 PRESSWIRE-6 February 2008-Research and Markets: Research and Markets: Analyze How Wyeth Will Perform In Light Of Patent Expiry for the Key Effexor and Protonix Franchises Prior To 2012(C)1994-2008 M2 COMMUNICATIONS LTD
RDATE:07022008
Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c81889) has announced the addition of Wyeth: PharmaVitae Profile to their offering
Related Results
AHP Posts Flat Earnings But Gears Up for Growth.
Court Takes Matter of Wyeth’s Motion for Preliminary Injunction Under Advisem…
West Nile Virus infection in a renal transplant recipient
Prevacid held slight lead in proton pump inhibitor sales to retailers for 200…
Colorado Medicaid instituted a limit of eight prescriptions per patient at an…
This analysis examines the historical and forecast performance for Wyeth in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline …
Read the rest of this article with a Free Trial at HighBeam Research.
